ICER Extends Influence Among US Insurers With AHIP Subscription Deal
AHIP arrangement is a big win for ICER and will facilitate access to the organization’s cloud-based cost effectiveness review platform for a broad range of payers, particularly small and mid-size companies that may not have the resources to subscribe to the service on their own.
You may also be interested in...
A review of grants by the organization to a range of recipients engaged in work on lowering drug prices.
Tufts study evaluates the extent and impact of manufacturer engagement with the Institute for Clinical and Economic Review while recent survey by Xcenda finds payer reliance on ICER reports is growing.
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.